GlassScriptPhysician profile
Kenzie Dent Smith
NPI 1609225911
$8,320.01
in general payments reported to CMS, 2019-2025
51 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $1,087 · 2021: $2,495 · 2022: $1,319 · 2023: $840 · 2024: $1,171 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,880 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,880.28 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,418.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $810.77 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $773.15 | 2021-2025 | Vraylar, Qulipta |
| Amgen INC. | $580.52 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $531.77 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $452.34 | 2020-2021 | |
| Astellas Pharma US INC | $445.38 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $431.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $376.92 | 2019-2025 | Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $247.54 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $206.11 | 2020-2022 | |
| Exact Sciences Corporation | $156.79 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $137.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $135.81 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.55 | 2019-2025 | Jascayd |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenzie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.